– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...
- These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- ...
Medical genetics company Invitae is partnering with research program Simons Searchlight to analyze rare genetic neurodevelopmental disorders through data sharing. Invitae will share its longitudinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results